Abstract
Aim: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems.
Methods: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on.
Discussion: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities.
Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented.
Keywords: Biotherapy, cancer stem cell, drug combination, drug resistance, neoplasm metastasis, personalized cancer therapy.
Reviews on Recent Clinical Trials
Title:Drug Combination in Clinical Cancer Treatments
Volume: 12 Issue: 3
Author(s): Da-Yong Lu*, Ting-Ren Lu, Nagendra Sastry Yarla, Hong-Ying Wu, Bin Xu, Jian Ding and Hong Zhu
Affiliation:
- School of Life Sciences, Shanghai University, Shanghai 200444,China
Keywords: Biotherapy, cancer stem cell, drug combination, drug resistance, neoplasm metastasis, personalized cancer therapy.
Abstract: Aim: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems.
Methods: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on.
Discussion: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities.
Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented.
Export Options
About this article
Cite this article as:
Lu Da-Yong*, Lu Ting-Ren , Yarla Sastry Nagendra , Wu Hong-Ying , Xu Bin , Ding Jian and Zhu Hong , Drug Combination in Clinical Cancer Treatments, Reviews on Recent Clinical Trials 2017; 12 (3) . https://dx.doi.org/10.2174/1574887112666170803145955
DOI https://dx.doi.org/10.2174/1574887112666170803145955 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
7-O-aminoalkyl-2,3-dehydrosilibinins: Synthesis and in vitro Anti-cancer Efficacy
Anti-Cancer Agents in Medicinal Chemistry Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases
Current Cancer Drug Targets Induction of Autophagic Cell Death in Apoptosis-resistant Pancreatic Cancer Cells using Benzo[α]phenoxazines Derivatives, 10-methyl-benzo[α]phenoxazine-5-one and benzo[α]phenoxazine-5-one
Anti-Cancer Agents in Medicinal Chemistry Life and Death of Nerve Cells: Therapeutic Cytokine Signaling Pathways
Current Signal Transduction Therapy Aging and Proteins: What Does Proteostasis Have to Do with Age?
Current Molecular Medicine Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Intrabody-Based Approaches to Cancer Therapy: Status and Prospects
Current Medicinal Chemistry Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Paracrine Provision of Lipids in the Immune System
Current Immunology Reviews (Discontinued) Antitumour Activity of Muricatacin Isomers and its Derivatives in Human Colorectal Carcinoma Cell HCT116
Anti-Cancer Agents in Medicinal Chemistry Antileukotriene Treatment in Children with Asthma - New Patents
Recent Patents on Inflammation & Allergy Drug Discovery Technological Advances in Preclinical Drug Evaluation: The Role of -Omics Methods
Current Medicinal Chemistry Acute Pain Management in Hospitalized Children
Reviews on Recent Clinical Trials Artepillin C Induces Selective Oxidative Stress and Inhibits Migration and Invasion in a Comprehensive Panel of Human Cervical Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Modeling of LIM-Kinase 2 Inhibitory Activity of Pyrrolopyrimidine Analogues: Useful in Treatment of Ocular Hypertension and Glaucoma
Medicinal Chemistry Low Dose Chest Computed Tomography, in Identifying Pulmonary Complications in Immunocompromised Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Current Respiratory Medicine Reviews Microextraction by Packed Sorbent of B Vitamins from Energy Bev erages Prior to Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry Assay
Current Chromatography Zinc as an Appetite Stimulator - The Possible Role of Zinc in the Progression of Diseases Such as Cachexia and Sarcopenia
Recent Patents on Food, Nutrition & Agriculture Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Current Drug Targets